U082 - Herpes Zoster: Controversies and Conundrums in Treatment and Prevention
Monday, March 4; 7:30 AM - 8:30 AM
Following this course, the attendee should be able to:
- Summarize the pathogenesis and key clinical features of herpes zoster, including unique presentations in special patient populations.
- Identify the best treatment regimens for herpes zoster based on recent literature, including evidence for and against measures to manage post-herpetic neuralgia.
- Outline, using case scenarios, systems-based prevention strategies for herpes zoster in health care institutions, including updated vaccination guidelines and hospital isolation policies.
During an inpatient consult for herpes zoster, have you ever been approached by a frantic staff or family member, worried that a pregnant contact will be 'infected' if they get too close? Have your patients asked about risk of having herpes zoster twice? Should they be vaccinated? In what timeline should antiviral therapy and prevention be employed? Is there evidence for prednisone or gabapentin? Cost and side effects? What about patients on biologics?
In case-based form, these and other complex but common scenarios will be examined using viral mechanistic and clinical clues and updated prevention and treatment guidelines.
- High, Whitney A., MD, JD: no financial relationships exist with commercial interests.
- Leslie, Kieron S., MBBS: no financial relationships exist with commercial interests.
- Rosamilia, Lorraine L., MD: no financial relationships exist with commercial interests.
- Tyring, Stephen K., MD, PhD: Agenus Inc. – I(Grants/Research Funding); AiCuris GmbH & Co. KG – I(Grants/Research Funding); Genocea Biosciences – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Nycomed Amersham – I(Grants/Research Funding); Vical Incorporated – I(Grants/Research Funding);
Dr. Rosamilia / Introduction and cases
Dr. High / Diagnosis and treatment
Dr. Leslie / Special populations
Dr. Tyring / Vaccination
Dr. Rosamilia / Conclusion